A review of the rationale for additional therapeutic interventions to attain lower LDL-c when Statin therapy is not enough

Current Atherosclerosis Reports

Volumn 14, Issue 1, 2012, Pages 33-40

  Shanes, Jeffrey G ^a,b  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b Cardiovascular Medicine   (United States)

Author keywords

Almonds; Bile acid sequestrants; Cholesterol; Cholestyramine; Colesevelam; Dietary portfolio; Ezetimibe; Fiber; Fibrates; LDL cholesterol; Niacin; Plant stanols; Plant sterols; Red yeast rice; Soy protein; Statins

Indexed keywords

BILE ACID SEQUESTRANT; CHOLESTIN; COLESEVELAM; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; ROSUVASTATIN; SIMVASTATIN; SOYBEAN PROTEIN; STANOZOLOL; STEROL;

ABDOMINAL PAIN; ALMOND; BLOATING; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONSTIPATION; DIETARY FIBER; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FAMILIAL HYPERCHOLESTEROLEMIA; HEARTBURN; HUMAN; HYPERCHOLESTEROLEMIA; LIVER; LOW DRUG DOSE; LOW FAT DIET; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRIENT; PARTICLE SIZE; REVIEW;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84857625955     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0222-z     Document Type: Review

References (48)

1. TA Pearson I Laurora H Chu S Kafonek 2000 The lipid treatment assessment project Arch Intern Med 160 459 467 10695686 10.1001/archinte.160.4.459 1:CAS:528:DC%2BD3cXhvFGhur8%3D
2. DW Russell 1992 Cholesterol biosynthesis and metabolism Cardiovasc Drugs Ther 6 103 110 1390320 10.1007/BF00054556 1:STN:280:DyaK3s%2Fgt1GqtA%3D%3D
3. SA Hill MJ McQueen 1997 Reverse cholesterol transport-a review of the process and its clinical implications Clin Biochem 30 517 525 9399019 10.1016/S0009-9120(97)00098-2 1:CAS:528:DyaK2sXnsl2ju7c%3D (Pubitemid 27506075)
4. DB Hunninghake EA Stein CA Dujovne, et al. 1993 The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia N Engl J Med 328 1213 1219 8464431 10.1056/ NEJM199304293281701 1:STN:280:DyaK3s3hvVKltw%3D%3D (Pubitemid 23115699)
5. A Jula J Marniemi H Risto, et al. 2002 Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial JAMA 287 598 605 11829698 10.1001/jama.287.5.598 1:CAS:528:DC%2BD38XhtVWqtbo%3D (Pubitemid 34252011)
6. DM Robinson GM Keating 2007 Colesevelam: a review of its use in hypercholesterolemia Am J Cardiovasc Drugs 6 453 465 10.2165/00129784-200707060- 00009 (Pubitemid 350256054)
7. The lipid research clinics program: the lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
8. W Insull P Toth W Mullican, et al. 2001 Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial Mayo Clin Proc 76 971 982 11605698 10.4065/76.10.971 1:CAS:528:DC%2BD3MXnvVCisrs%3D (Pubitemid 32946008)
9. HE Bays RB Goldberg KE Truitt MR Jones 2008 Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin Arch Intern Med 168 1975 1983 18852398 10.1001/archinte.168.18.1975 1:CAS:528:DC%2BD1cXht12hsLrI
10. HE Bays M Davidson MR Jones SL Abby 2006 Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-Reactive protein when added to statins in patients with hypercholesterolemia Am J Cardiol 97 1198 1205 16616026 10.1016/j.amjcard.2005.11.039 1:CAS:528:DC%2BD28XjsFOnsbk%3D
11. A Pandor RM Ara I Tumor, et al. 2008 Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials J Int Med 265 568 580 10.1111/j.1365-2796.2008. 02062.x
12. L Baruch S Agarwal B Gupta, et al. 2009 Effect on serum lipid levels of switching dose of ezetimibe from 10 to 5 mg Am J Cardiol 103 1568 1571 19463517 10.1016/j.amjcard.2009.01.365 1:CAS:528:DC%2BD1MXmtlOltrY%3D
13. T Kosoglou P Statkevich AO Johnson-Levonas, et al. 2005 Ezetimibe a review of its metabolism, pharmacokinetics and drug interactions Clin Pharmacokinet 44 467 494 15871634 10.2165/00003088-200544050-00002 1:CAS:528:DC%2BD2MXlvVCrtbs%3D (Pubitemid 40733733)
14. MJ Zema 2005 Colesevelam HCI and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia Am J Ther 12 306 310 16041193 10.1097/01.mjt.0000155109. 69831.a3 (Pubitemid 41391808)
15. HE Bays MH Davidson R Massaad, et al. 2011 Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE study) Am J Cardiol 108 523 530 21596364 10.1016/j.amjcard.2011.03.079 1:CAS:528: DC%2BC3MXpsFGisLY%3D
16. R Huijgen EJ Abbink E Bruckert, et al. 2010 Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial Clin Ther 32 615 625 20435231 10.1016/j.clinthera.2010.04.014 1:CAS:528:DC%2BC3cXosVSnurg%3D
17. AJ Taylor TC Villines EJ Stanek, et al. 2009 Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2113 2122 19915217 10.1056/NEJMoa0907569 1:CAS:528:DC%2BD1MXhsFSnsLzP
18. SM Grundy JI Cleeman NB Merz, et al. 2004 Implications of recent clinical trials for the national cholesterol education program adult treatment Panel III guidelines Circulation 110 227 239 15249516 10.1161/01.CIR.0000133317.49796.0E (Pubitemid 38924592)
19. H Buchwald RL Varco JR Boen, et al. 1998 Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH Arch Intern Med 158 1253 1261 9625405 10.1001/archinte.158.11.1253 1:STN:280: DyaK1c3oslSrtQ%3D%3D (Pubitemid 28252490)
20. TA Pearson CM Ballantyne E Veltri, et al. 2009 Pooled analyses of effects on C-Reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy Am J Cardiol 103 369 374 19166691 10.1016/j.amjcard. 2008.09.090 1:CAS:528:DC%2BD1MXhtVeju70%3D
21. JM Morgan CM Carey A Lincoff DM Capuzzi 2004 The effects of niacin on lipoprotein subclass distribution Prev Cardiol 7 182 189 15539965 10.1111/j.1520-037X.2004.3129.x 1:CAS:528:DC%2BD2MXht12huw%3D%3D
22. A Goldberg P Alagona Jr DM Capuzzi, et al. 2000 Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia Am J Cardiol 85 1100 1105 10781759 10.1016/S0002-9149(00)00703-7 1:CAS:528:DC%2BD3cXislaqsbw%3D (Pubitemid 30214256)
23. CM Ballantyne MH Davidson JM McKenney, et al. 2008 Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high dose) study J Clin Lipidol 2 79 90 21291724 10.1016/j.jacl.2008.02.004 (Pubitemid 351372956)
24. VS Kamanna ML Kashyap 2000 Mechanism of action of niacin on lipoprotein metabolism Curr Atheroscler Rep 2 36 46 11122723 10.1007/s11883-000-0093-1 1:STN:280:DC%2BD3MzptlWqug%3D%3D
25. B Staels J Dallongeville J Auwerx, et al. 1998 Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 98 2088 2093 9808609 1:CAS:528:DyaK1cXnsFCisr8%3D (Pubitemid 28512236)
26. PH Jones MH Davidson AC Goldberg, et al. 2009 Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: pooled analysis of three phase 3, 12-week randomized, controlled studies J Clin Lipidol 3 125 137 21291802 10.1016/j.jacl.2009.02.007
27. AC Goldberg G Schonfeld EB Feldman, et al. 1989 Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study Clin Ther 1 69 83 (Pubitemid 19112878)
28. J Wang Z Lu J Chi 1997 Current therapeutic research, clinical and experimental Curr Ther Res 58 964 978 10.1016/S0011-393X(97)80063-X (Pubitemid 28060054)
29. J Staunton KJ Weissman 2001 Polyketide biosynthesis: a millennium review R Soc Chem 18 380 416 1:CAS:528:DC%2BD3MXltlyqsbo%3D (Pubitemid 32773840)
30. W Ahmed N Khan CJ Glueck, et al. 2009 Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients Transl Res 153 11 16 19100953 10.1016/j.trsl.2008.11.002 1:CAS:528:DC%2BD1cXhsFagsLvE
31. L Marcoff PD Thompson 2007 The role of coenzyme Q10 in statin-associated myopathy a systematic review J Am Coll Cardiol 49 2231 2237 17560286 10.1016/j.jacc.2007.02.049 1:CAS:528:DC%2BD2sXmtlWisrg%3D (Pubitemid 46856819)
32. M Gadarla AK Kearns PD Thompson 2008 Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins Am J Cardiol 101 1747 1748 18549851 10.1016/j.amjcard.2008.02.061 1:CAS:528:DC%2BD1cXnt1SltbY%3D
33. E Bruckert G Hayem S Dejager, et al. 2005 Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study Cardiovasc Drugs Ther 19 403 414 16453090 10.1007/s10557-005-5686-z 1:CAS:528:DC%2BD28XhtlGku7w%3D (Pubitemid 43228152)
34. D Heber I Yip JM Ashley, et al. 1999 Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement Am J Clin Nutr 69 231 236 9989685 1:CAS:528:DyaK1MXovVKitQ%3D%3D (Pubitemid 29065544)
35. DJ Becker RY Gordon SC Halbert, et al. 2009 Red yeast rice for dyslipidemia in statin-intolerant patients a randomized trial Ann Intern Med 150 830 839 19528562
36. J Liu J Zhang S Grimsgaard, et al. 2006 Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials Chin Med 1 4 17302963 10.1186/1749-8546-1-4
37. Z Lu W Kou B Du, et al. 2008 Effect of Xuezhikang, an extract from red yeast chinese rice, on coronary events in a Chinese population with previous myocardial infarction Am J Cardiol 101 1689 1693 18549841 10.1016/j.amjcard. 2008.02.056
38. RY Gordon T Cooperman W Obermeyer DJ Becker 2010 Marked variability of monacolin levels in commercial red yeast rice products Arch Intern Med 170 1722 1727 20975018 10.1001/archinternmed.2010.382 1:CAS:528:DC%2BC3cXhsFaitrbL
39. L Brown B Rosner WW Willett FM Sacks 1999 Cholesterol-lowering effects of dietary fiber: a meta-analysis Am J Clin Nutr 69 30 42 9925120 1:CAS:528:DyaK1MXjvFSmsg%3D%3D (Pubitemid 29031248)
40. MB Katan SM Grundy P Jones, et al. 2003 Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels Mayo Clin Proc 78 965 978 12911045 10.4065/78.8.965 1:CAS:528:DC%2BD3sXmvFShs70%3D (Pubitemid 36936128)
41. L Jakulj MD Trip T Sudhop, et al. 2005 Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels J Lipid Res 46 2692 2698 16162943 10.1194/jlr.M500260- JLR200 1:CAS:528:DC%2BD2MXhtlWmsb7M (Pubitemid 43107481)
42. SA Linnebur WH Capell JJ Saseen, et al. 2007 Plant sterols added to combination statin and colesevelam hydrochloride therapy failed to lower low-density lipoprotein cholesterol concentrations J Clin Lipidol 1 626 633 21291705 10.1016/j.jacl.2007.10.004 (Pubitemid 350218044)
43. JW Anderson BM Johnstone ME Cook-Newell 1995 Meta-analysis of the effects of soy protein intake on serum lipids N Engl J Med 333 276 282 7596371 10.1056/NEJM199508033330502 1:CAS:528:DyaK2MXntlKht74%3D
44. JR Crouse III T Morgan JG Terry, et al. 1999 A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins Arch Intern Med 159 2070 2076 10510993 10.1001/archinte.159.17.2070 1:CAS:528:DyaK1MXms12mtro%3D (Pubitemid 29453595)
45. JW Erdman Jr 2000 Soy protein and cardiovascular disease: a statement for healthcare professionals from the nutrition committee of the AHA Circulation 102 2555 2559 11076833 1:CAS:528:DC%2BD3cXptVSjsbk%3D
46. GE Fraser 1999 Nut consumption, lipids, and risk of a coronary event Clin Cardiol 22 III-11 III-15 10.1002/clc.4960221504 1:STN:280:DyaK1MzjvVCruw%3D%3D
47. DJA Jenkins CWC Kendall A Marchie, et al. 2002 Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial Circulation 106 1327 1332 12221048 10.1161/01.CIR.0000028421.91733.20 1:CAS:528:DC%2BD38XntVKks7Y%3D (Pubitemid 35013034)
48. DJA Jenkins CWC Kendall A Marchie, et al. 2003 Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-Reactive protein JAMA 290 502 510 12876093 10.1001/jama.290.4.502 1:CAS:528:DC%2BD3sXls1yjsLk%3D (Pubitemid 37430504)